Marker 01

Marker 02

Marker 03

Marker 04

Marker 05

Marker 06

Marker 07

Marker 09

Marker 10

Marker 11

“If you’re not going overseas, you’re going out,” says Dr. Xingli Wang, Co-President of Fosun Pharma. He tells Bloomberg Intelligence’s Sam Fazeli how Fosun is transitioning from generics to novel medicines and positioning itself as a global innovator. With 90% of R&D now focused on oncology, autoimmune and neurodegenerative diseases, Wang details Fosun’s ambition to move from a China-based manufacturer to a multinational developer with true blockbuster potential. He also reflects on how disciplined capital investment, scientific partnerships and cultural persistence could make Fosun the “Takeda of China.”
Listen to this episode of Vanguards of Health Care on Apple Podcasts and Spotify

&ldquo;If you&rsquo;re not going overseas, you&rsquo;re going out,&rdquo; says Dr. Xingli Wang, Co-President of Fosun Pharma. He tells Bloomberg Intelligence&rsquo;s Sam Fazeli how Fosun is transitioning from generics to novel medicines and positioning itself as a global innovator. With 90% of R&amp;D now focused on oncology, autoimmune and neurodegenerative diseases, Wang details Fosun&rsquo;s ambition to move from a China-based manufacturer to a multinational developer with true blockbuster potential. He also reflects on how disciplined capital investment, scientific partnerships and cultural persistence could make Fosun the &ldquo;Takeda of China.&rdquo; Listen to this episode of Vanguards of Health Care on Apple Podcasts and Spotify

Vanguards of Healthcare is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Healthcare is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Healthcare by Bloomberg Intelligence

Fosun Pharma’s Drive Beyond China

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/5fe8fe3a-5078-49b5-b7aa-b39800f53153/transcript